Cisplatin is a known ototoxic chemotherapy drug, causing irreversible hearing loss.
Evidence has shown that cisplatin causes inner ear damage as a result of adduct formation …

Administration of cisplatin, a common chemotherapeutic drug, has an inevitable side effect
of sensorineural hearing loss. The main etiologies are stria vascularis injury, spiral ganglion …

Cisplatin-induced ototoxicity in humans is more predominant in the cochlea than in the
vestibule. Neither definite nor substantial vestibular dysfunction after cisplatin treatment has …

Cisplatin is a highly effective antineoplastic agent used to treat solid tumors. Unfortunately,
the administration of this drug leads to significant side effects, including ototoxicity …

Cisplatin chemotherapy often causes permanent hearing loss, which leads to a multifaceted
decrease in quality of life. Identification of early cisplatin-induced cochlear damage would …

Cisplatin is a potent antineoplastic agent widely used for a variety of cancer types.
Unfortunately, its use leads to dose limiting side effects such as ototoxicity. Up to 93% of …

Cis-diamminedichloroplatinum (cisplatin) is an effective chemotherapeutic drug for cancer
therapy. However, most patients treated with cisplatin are at a high risk of ototoxicity, which …

Cisplatin is a first-line chemotherapeutic agent in the treatment of malignant tumors with
remarkable clinical effects and low cost. However, the ototoxicity and neurotoxicity of …

Cisplatin belongs to platinum-based drugs and is widely used in cancer chemotherapy.
Ototoxicity is one of the major dose limiting side-effects of cisplatin. For toxicity to occur …

Evidence of significant hearing loss during the early days of use of cisplatin as a
chemotherapeutic agent in cancer patients has stimulated research into the causes and …